EGFR inhibition by monoclonal antibodies or small molecule TKIs has been approved for the treatment of tumor entities like RAS wild-type colorectal cancers [28], HNSCC [29], and EGFR-mutated NSCLC [16, 30]. Here, EGFR is linked to colorectal cancer.